Trials / Recruiting
RecruitingNCT06925724
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
A Phase 2 Study of Ivonescimab (Bispecific Antibody Against PD1 and VEGF) For the Treatment of Endometrial (EC) and Cervical (CC) Cancers
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivonescimab | Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes) |
Timeline
- Start date
- 2025-04-04
- Primary completion
- 2027-04-01
- Completion
- 2027-04-04
- First posted
- 2025-04-13
- Last updated
- 2026-03-25
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06925724. Inclusion in this directory is not an endorsement.